Potentiation of PD-L1 blockade with a potency-matched dual cytokine–antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains

Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity

(2018) Barbara Ziffels et al.   Immunotherapy

NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data

(2017) Vanessa Jurtz et al.   JOURNAL OF IMMUNOLOGY

Potency-matched Dual Cytokine–Antibody Fusion Proteins for Cancer Therapy

(2017) Roberto De Luca et al.   MOLECULAR CANCER THERAPEUTICS

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

(2017) Vinod P. Balachandran et al.   NATURE

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy

(2017) Marta Łuksza et al.   NATURE

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

(2017) Diego Chowell et al.   SCIENCE

Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab

(2017) Greta Garrido et al.   Frontiers in Pharmacology

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

(2017) Christian Klein et al.   OncoImmunology

Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma

(2016) Jens Jakob et al.   CANCER

A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study

(2016) David Planchard et al.   Clinical Lung Cancer

Immunocytokines for cancer treatment: past, present and future

(2016) Dario Neri et al.   CURRENT OPINION IN IMMUNOLOGY

Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions

(2016) Franziska Bootz et al.   DRUG DISCOVERY TODAY

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

(2016) Suzanne I.S. Mosely et al.   Cancer Immunology Research

Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format

(2016) Sina Fellermeier et al.   OncoImmunology

Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study

(2015) Riccardo Danielli et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody fusions with immunomodulatory proteins for cancer therapy

(2015) Dafne Müller   PHARMACOLOGY & THERAPEUTICS

IL-2: The First Effective Immunotherapy for Human Cancer

(2014) S. A. Rosenberg   JOURNAL OF IMMUNOLOGY

Emerging classes of armed antibody therapeutics against cancer

(2014) Christian Hess et al.   MedChemComm

Murine leukemia virus envelope gp70 is a shared biomarker for the high-sensitivity quantification of murine tumor burden

(2014) Francesca Scrimieri et al.   OncoImmunology

The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer

(2013) Teresa Hemmerle et al.   INTERNATIONAL JOURNAL OF CANCER

A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity

(2013) S. D. Gillies   PROTEIN ENGINEERING DESIGN & SELECTION

Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia

(2013) K. L. Gutbrodt et al.   Science Translational Medicine

Antibody–cytokine fusion proteins

(2012) Roland E. Kontermann   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Immunocytokines: a novel class of potent armed antibodies

(2012) Nadine Pasche et al.   DRUG DISCOVERY TODAY

Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours

(2012) G. Spitaleri et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Intratumoral hu14.18-IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention

(2012) R. K. Yang et al.   JOURNAL OF IMMUNOLOGY

The Immunocytokine L19–IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF

(2012) Kathrin Schwager et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma

(2012) Francesco Papadia et al.   JOURNAL OF SURGICAL ONCOLOGY

A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

(2011) T. K. Eigentler et al.   CLINICAL CANCER RESEARCH

Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions

(2011) Katharina Frey et al.   EXPERIMENTAL DERMATOLOGY

Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery

(2011) Kerstin Galler et al.   HISTOCHEMISTRY AND CELL BIOLOGY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer

(2011) Kathrin Schwager et al.   Head and Neck Optical Diagnostics Society

The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma

(2010) Manfred Johannsen et al.   EUROPEAN JOURNAL OF CANCER

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma

(2009) Christoph Schliemann et al.   LEUKEMIA RESEARCH

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculaturein vivo

(2008) Alessandra Villa et al.   INTERNATIONAL JOURNAL OF CANCER